Antithrombotic treatment during acute inflammatory complications of patients affected by postphlebitic syndrome: LMW-heparin versus standard heparin.
Seventy seven patients affected by postphlebitic syndrome (PPS) during acute inflammatory and/or obstructive complications were controlled. Thirty nine patients were treated with a new low molecular weight heparin (Fluxum), 16,000 I.U. AXa/day subcutaneously for 10 days and, subsequently, 8,000 I.U. AXa/day subcutaneously for up to 50 days. Thirty eight patients were treated with 20,000 I.U./day i.v. for 10 days of sodium heparin and, subsequently, with 12,500 I.U./day of calcium heparin by subcutaneous injection for up to 50 days. Clinical symptoms (pain, oedema, hyperemia, rashes, itching, dermatitis, ulceration) and instrumental patterns (Doppler) were recorded. Fluxum had an evident effect on the improvement of patient's clinical performance during acute complications of PPS.
Verardi
S
S
Department of General Surgery, S. Eugenio Hospital, II University of Rome.
Ippoliti
A
A
Pistolese
G R
GR
D000368:Aged; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010689:Phlebitis / Q000188:drug therapy* / Q000209:etiology; D011186:Postphlebitic Syndrome / Q000150:complications*; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology
D006495:Heparin, Low-Molecular-Weight; C006871:calcium heparin; D006493:Heparin